Database Query Results : , , MEK

MEK, Mitogen-Activated Protein Kinase Kinase: Click to Expand ⟱
Source:
Type: protein kinase
MEK (Mitogen-Activated Protein Kinase Kinase) is a protein kinase that plays a crucial role in the regulation of cell growth, differentiation, and survival.
MEK is often overexpressed or mutated, leading to the activation of downstream signaling pathways that promote cell growth, survival, and metastasis. MEK inhibitors have been developed as a therapeutic strategy to target cancer cells and inhibit their growth.
Scientific Papers found: Click to Expand⟱
1539- Api,  LT,    Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells
- in-vitro, Liver, HepG2
SREBP2↓, eff↑, p‑MEK↓, p‑ERK↓,
2606- Ba,    Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma
- Review, HCC, NA
ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,
2694- BBR,    Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells
- in-vitro, BC, NA
IL8↓, TumCI↓, EGFR↓, MEK↓, ERK↓, TGF-β1↓, VEGF↓,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
726- Bor,    Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open
- Review, NA, NA
NAD↝, SAM-e↝, PSA↓, IGF-1↓, Cyc↓, P21↓, p‑MEK↓, p‑ERK↓, ROS↑, SOD↓, Catalase↓, MDA↑, GSH↓, IL1↓, IL6↓, TNF-α↓, BRAF↝, MAPK↝, PTEN↝, PI3K/Akt↝, eIF2α↑, ATF4↑, ATF6↑, NRF2↑, BAX↑, BID↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓,
2979- CUR,  GB,    Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
- in-vitro, Lung, H157 - in-vitro, Lung, H1299
EGFR↓, Sp1/3/4↓, ERK↓, MEK↓, Akt↓, S6K↓,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2908- LT,    Luteolin attenuates neutrophilic oxidative stress and inflammatory arthritis by inhibiting Raf1 activity
- in-vitro, Arthritis, NA
*ROS↓, *p‑ERK↓, *p‑MEK↓, *Raf↓,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1/CCND1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1271- NCL,    Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
- vitro+vivo, Ovarian, SKOV3
Wnt/(β-catenin)↓, mTOR↓, STAT3↓, NF-kB↓, NOTCH↓, TumCG↓, Apoptosis↑, MEK↓, ERK↓, mitResp↓, Glycolysis↓, ROS↑, JNK↑,
4704- PTS,  Cisplatin,    Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
- in-vitro, Bladder, NA
PI3K↓, mTOR↓, P70S6K↓, MEK↑, ERK↑, ChemoSen↑, TumAuto↑,
3372- QC,  FIS,  KaempF,    Anticancer Potential of Selected Flavonols: Fisetin, Kaempferol, and Quercetin on Head and Neck Cancers
- Review, HNSCC, NA
ROCK1↑, TumCCA↓, HSPs↓, RAS↓, ROS↑, Ca+2↑, MMP↓, Cyt‑c↑, Endon↑, MMP9↓, MMP2↓, MMP7↓, MMP-10↓, VEGF↓, NF-kB↓, p65↓, iNOS↓, COX2↓, uPA↓, PI3K↓, FAK↓, MEK↓, ERK↓, JNK↓, p38↓, cJun↓, FOXO3↑,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
1213- VitK2,    Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4
- in-vitro, HCC, HepG2
HSD17B4↓, Akt↓, MEK↓, ERK↓, STAT3↓, TumCP↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 18

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   GSH↓, 1,   GSH↑, 1,   H2O2↑, 1,   lipid-P↓, 1,   MDA↑, 1,   NRF2↑, 1,   ROS↑, 8,   ROS⇅, 1,   SAM-e↝, 1,   SIRT3↑, 1,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   CDC2↓, 1,   CDC25↓, 1,   MEK↓, 11,   MEK↑, 1,   p‑MEK↓, 5,   mitResp↓, 1,   MKK4↓, 1,   MMP↓, 6,   Raf↓, 4,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   ACC↑, 1,   AMPK↑, 1,   cMyc↓, 2,   Glycolysis↓, 2,   HSD17B4↓, 1,   NAD↝, 1,   PI3K/Akt↝, 1,   S6K↓, 1,   p‑S6K↓, 1,   SREBP2↓, 1,  

Cell Death ⓘ

Akt↓, 7,   p‑Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 3,   BAD↑, 1,   Bak↑, 1,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 4,   BID↑, 1,   BIM↓, 1,   BIM↑, 2,   BMP2↓, 1,   Casp↑, 2,   Casp2↑, 1,   Casp3↑, 6,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 4,   Cyt‑c↑, 3,   Diablo↑, 1,   DR4↑, 1,   DR5↑, 2,   Endon↑, 1,   Fas↑, 2,   iNOS↓, 1,   JNK↓, 1,   JNK↑, 2,   MAPK↓, 2,   MAPK↝, 1,   Mcl-1↓, 2,   NOXA↑, 1,   p27↑, 1,   p38↓, 2,   survivin↓, 1,   Telomerase↓, 2,   TRAIL↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 2,   HATs↑, 1,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   CHOP↑, 1,   eIF2α↑, 1,   ER Stress↑, 1,   HSP70/HSPA5↓, 1,   HSPs↓, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 3,   P53↑, 2,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 2,   CDK4↓, 2,   Cyc↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   P21↓, 1,   Securin↓, 1,   TumCCA↓, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

BRAF↝, 1,   CD133↓, 1,   CD24↓, 1,   cFos↓, 1,   CSCs↓, 1,   Diff↓, 1,   EMT↓, 3,   ERK↓, 10,   ERK↑, 1,   p‑ERK↓, 6,   FOXO3↑, 2,   HDAC↓, 1,   IGF-1↓, 1,   mTOR↓, 5,   p‑mTORC1↓, 1,   n-MYC↓, 1,   Nestin↓, 1,   NOTCH↓, 2,   P70S6K↓, 1,   PI3K↓, 6,   PTEN↑, 2,   PTEN↝, 1,   RAS↓, 2,   SOX2↓, 1,   STAT3↓, 4,   TCF↑, 1,   TumCG↓, 2,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,   ZFX↓, 1,  

Migration ⓘ

Ca+2↑, 2,   CD31↓, 1,   E-cadherin↓, 1,   F-actin↓, 1,   FAK↓, 2,   Fibronectin↓, 1,   MMP-10↓, 1,   MMP2↓, 6,   MMP7↓, 1,   MMP9↓, 6,   MMPs↓, 2,   N-cadherin↓, 1,   ROCK1↑, 1,   Snail↓, 1,   TGF-β↓, 1,   TGF-β1↓, 1,   TIMP1↓, 1,   TIMP2↓, 1,   TumCI↓, 4,   TumCMig↓, 4,   TumCP↓, 3,   TumMeta↓, 1,   uPA↓, 5,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   ATF4↑, 1,   EGFR↓, 5,   Hif1a↓, 2,   VEGF↓, 6,   VEGFR2↓, 2,  

Immune & Inflammatory Signaling ⓘ

CCR7↓, 1,   COX2↓, 5,   CXCR4↓, 1,   IFN-γ↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL2↑, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 2,   JAK2↓, 1,   MCP1↓, 1,   MDSCs↓, 1,   NF-kB↓, 6,   NF-kB↑, 1,   p65↓, 3,   PGE2↓, 3,   PSA↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 5,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   eff↓, 1,   eff↑, 8,   eff↝, 1,   RadioS↑, 2,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

BRAF↝, 1,   EGFR↓, 5,   IL6↓, 2,   PSA↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   neuroP↑, 1,  
Total Targets: 196

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Mitochondria & Bioenergetics ⓘ

p‑MEK↓, 1,   Raf↓, 1,  

Cell Death ⓘ

Akt↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,   PI3K↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  
Total Targets: 7

Scientific Paper Hit Count for: MEK, Mitogen-Activated Protein Kinase Kinase
2 Luteolin
2 Berberine
2 Fisetin
2 Sulforaphane (mainly Broccoli)
2 Silymarin (Milk Thistle) silibinin
1 Apigenin (mainly Parsley)
1 Baicalein
1 Boron
1 Curcumin
1 gefitinib, erlotinib
1 Myricetin
1 Niclosamide (Niclocide)
1 Pterostilbene
1 Cisplatin
1 Quercetin
1 Kaempferol
1 Thymoquinone
1 Vitamin K2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:860  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page